Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, and its news flow reflects active clinical development, collaborations and capital markets activity. Company updates frequently highlight progress with cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and certain lymphomas, as well as broader pipeline and platform achievements.
News for C4 Therapeutics often centers on clinical data milestones, such as Phase 1 results for cemsidomide in combination with dexamethasone, acceptance of data for oral presentation at scientific meetings, and plans for registrational trials like the Phase 2 MOMENTUM study. Releases also cover developments in non-Hodgkins lymphoma cohorts and updates on other degrader programs, including CFT8919 for EGFR-mutant non-small cell lung cancer and CFT1946 for BRAF V600 mutant solid tumors.
Investors following CCCC news will also see collaboration announcements and research milestones. Examples include the clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide with elranatamab in multiple myeloma, milestone achievements in partnerships with Biogen, Roche and Merck KGaA, Darmstadt, Germany, and regulatory steps such as IND acceptance for BIIB142, an IRAK4 degrader designed by C4 Therapeutics.
Financial and corporate updates are another key news category. The company regularly reports quarterly financial results, cash runway guidance, equity offerings and changes to its capital structure via press releases and Form 8-K filings. For readers tracking CCCC, this news page aggregates these clinical, scientific, collaboration and financing updates in one place, making it easier to monitor how C4 Therapeutics is advancing its targeted protein degradation pipeline over time.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement non-qualified stock option grant of 85,480 shares to one new employee, approved March 9, 2026. The exercise price equals the closing market price on the grant date. Vesting: four years with 25% after year one, then 36 monthly installments.
The grant was made as a material inducement under Nasdaq Listing Rule 5635(c)(4) and is subject to continued employment through each vesting date.
C4 Therapeutics (Nasdaq: CCCC) reported 2025 results and program progress on Feb 26, 2026. Key items: cemsidomide moved into a Phase 2 MOMENTUM trial with first patient dosed and a recommended Phase 2 dose of 100 µg. Cash, cash equivalents and marketable securities were $297.1M at Dec 31, 2025, providing runway to the end of 2028. Company raised $125M in October 2025 and earned a $2M Biogen milestone; Phase 1b combo trial with elranatamab is on track for Q2 2026.
C4 Therapeutics (Nasdaq: CCCC) announced management will participate in two March 2026 healthcare conferences with live webcasts available for investors. Management will present at the TD Cowen conference on March 3, 2026 at 11:50 AM ET and participate in Barclays on March 10, 2026 at 8:00 AM ET.
Webcasts will stream on the company’s Investor website, with archived replays available for about 90 days after each event.
C4 Therapeutics (Nasdaq: CCCC) dosed the first patient in the Phase 2 MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for relapsed/refractory multiple myeloma.
The open-label, single-arm study will enroll ~100 patients at the 100 µg dose (14 days on/14 days off dosing) with overall response rate as the primary endpoint. Enrollment is expected to complete in Q1 2027, and a Phase 1b combination trial with elranatamab is on track to initiate in Q2 2026.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options covering 162,880 shares to one new employee, approved by independent directors on February 9, 2026.
The options have an exercise price equal to the closing share price on the grant date and vest over four years (25% after one year, then monthly over three years), subject to continued employment.
C4 Therapeutics (NASDAQ: CCCC) announced that company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
The fireside chat is scheduled for Wednesday, February 11, 2026 at 11:30 AM ET. A live webcast will be available on the company’s Investors website, with an archived replay accessible for approximately 90 days.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options to one new employee approved by the independent directors on the Organization, Leadership and Compensation Committee.
The grant covers 85,480 shares, was made on January 26, 2026, and has an exercise price equal to the closing price of C4T common stock on the grant date. The options vest over four years: 25% on the first-year anniversary of the employee's start date and the remainder in 36 equal monthly installments, subject to continued employment.
C4 Therapeutics (Nasdaq: CCCC) outlined milestones through 2028 focused on advancing cemsidomide as an IKZF1/3 degrader and progressing internal discovery in inflammation and neuro‑degeneration. Key near‑term actions include initiating the Phase 2 MOMENTUM trial in Q1 2026 (recommended Phase 2 dose: 100 µg) with planned 12‑month enrollment, and initiating a Phase 1b combo trial with elranatamab in Q2 2026. Reported Phase 1 ORR was 40% at 75 µg and 53% at 100 µg. The company says cash runway extends to end of 2028, target NDA submission for fourth‑line cemsidomide by year‑end 2028, and up to three INDs for discovery programs by year‑end 2028.
C4 Therapeutics (Nasdaq: CCCC) management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 3, 2025 at 3:25 pm ET. A live webcast of the presentation will be available on the company’s Investors website and an archived replay will be accessible for approximately 90 days after the event.
This presentation provides an opportunity for investors to hear management discuss clinical programs and corporate strategy.
C4 Therapeutics (Nasdaq: CCCC) reported Q3 2025 results and program updates on November 6, 2025. Key highlights include a completed equity offering that raised $125 million in gross proceeds (with potential for an additional $225 million if outstanding warrants are exercised), which the company says extends its runway to end of 2028. Clinically, cemsidomide showed a 53% overall response rate (ORR) at the 100 µg dose and 40% ORR at 75 µg in a Phase 1 multiple myeloma trial, with a median duration of response of 9.3 months. C4T entered a collaboration with Pfizer to test cemsidomide plus elranatamab and plans a Phase 2 MOMENTUM trial in Q1 2026 and a Phase 1b combination trial in Q2 2026. Financially, Q3 revenue was $11.2 million, net loss was $32.2 million, and cash and marketable securities were $199.8 million as of September 30, 2025 (excluding the October 2025 $125 million gross proceeds).